Petlife Pharmaceuticals (PTLF) Stock Statistics & Valuation Metrics
Total Valuation
Petlife Pharmaceuticals has a market cap or net worth of $22.43K. The enterprise value is $682.60B.
- Market Cap
- $22.43K
- Enterprise Value
- $682.60B
Share Statistics
Petlife Pharmaceuticals has 222,120,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 222,120,650
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Petlife Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- 0
- Profits Per Employee
- -23.26M
- Employee Count
- 1
- Asset Turnover
- ―
- Inventory Turnover
- ―
Valuation Ratios
The current PE Ratio of Petlife Pharmaceuticals is -0.00. Petlife Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.00
- Price to FCF
- -0.06
- Price to Operating Cash Flow
- -0.02
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Petlife Pharmaceuticals had revenue of 0 and earned -23.26M in profits. Earnings per share was -0.33.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -22.66M
- Pretax Income
- -23.26M
- Net Income
- -23.26M
- EBITDA
- -22.87M
- Earnings Per Share (EPS)
- -0.33
Cash Flow
In the last 12 months, operating cash flow was -261.90K and capital expenditures 0, giving a free cash flow of -261.90K billion.
- Operating Cash Flow
- -261.90K
- Free Cash Flow
- -261.90K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Petlife Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1620.93%
- Earnings Yield
- -338010.96%
Stock Price Statistics
- Beta
- 10.61
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Taxes
In the past 12 months, Petlife Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- ―
Enterprise Valuation
Petlife Pharmaceuticals EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -2.14.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.03
- EV to Free Cash Flow
- -2.14
- EV to Operating Cash Flow
- -2.14
Balance Sheet
Petlife Pharmaceuticals has $7,856.00 in cash and marketable securities with $801.65K in debt, giving a net cash position of -$793.80K billion.
- Cash & Marketable Securities
- $7,856.00
- Total Debt
- $801.65K
- Net Cash
- -$793.80K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Petlife Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
